Clinical Trial Update: Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria [Phase 2]

View source ↗

Summary

A Phase 2 trial of Ritlecitinib (PF-06651600) for chronic spontaneous urticaria has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Ritlecitinib (ritlecitinib)

Snippet

Sponsor: Ahuva D Cices | Conditions: Chronic Spontaneous Urticaria, CSU | Phase 2 | Status: WITHDRAWN